Magle Group SEK 26.6m Capital Raise | Q4 2024

About Magle Group 

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise, Magle PharmaCept – an established sales and marketing company for development and direct sales of the Group’s medical technology products and Magle Biopolymers A/S – a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com, www.maglegroup.com, www.maglepharmacept.com and www.maglebiopolymers.com. 

Press release

Background and motive 

The proceeds from the Directed Share Issue are intended to be used to advance key projects that reinforce Magle Group’s position in innovative medical solutions and support the group’s ongoing structural and organisational changes following recent mergers. These initiatives include: 

• Commencing the Genicular Artery Embolisation (GAE) study with EmboCept® S. A multi-centre clinical study with key opinion leader support. GAE is a minimally invasive procedure designed to treat osteoarthritis-related knee pain by reducing blood flow to the genicular arteries, which are involved in inflammation and pain pathways. The study intends to validate the efficacy and safety of EmboCept® S in this application, broadening its clinical utility.
• Advancing the SmartPAN® clinical study. A first-in-class solution aimed at enhancing pancreatic surgery outcomes. SmartPAN® is a DSM-based bioindicator used to detect anastomotic leaks during pancreatic surgery. The study is supported by a leading pancreatic surgical centre and a network of key opinion leaders, further solidifying its position as a pioneering product. This initiative will build on the successful market openings in Germany, Austria, Greece, and Singapore and generate critical clinical evidence to support a future market entry into the United States.
• Undertaking biocompatibility testing for MicroSeal. A dextran-based surgical product designed for advanced surgical applications. The testing will explore three distinct formulations of MicroSeal, each tailored for use in different surgical scenarios. This innovative approach emphasizes the product's biocompatibility and biodegradability, ensuring it meets the highest standards for patient safety and environmental sustainability. By offering versatile formulations, MicroSeal aims to address diverse surgical needs while maintaining its bio-friendly profile. 

Website: https://maglegroup.com/